5 employees
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas.
2020
$46M
from 4 investors over 4 rounds
Innolake Biopharm raised $14M on June 5, 2023
Investors: WuXi Biologics
Innolake Biopharm raised $46M on January 1, 2021
Investors: 华盖资本有限责任公司, WuXi Biologics and CDH Investments